Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00147
|
|||||
| Drug Name |
Ivermectin
|
|||||
| Synonyms |
IVERMECTIN; Ivermectin B1a; Dihydroavermectin B1a; 22,23-Dihydroavermectin B1a; 71827-03-7; avermectin H2B1a; UNII-91Y2202OUW
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Strongyloidiasis due to nematode parasite [ICD11: 1F6B] | Approved | [1] | |||
| Therapeutic Class |
Antiprotozoal Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C48H74O14
|
|||||
| Canonical SMILES |
CCC(C)C1C(CCC2(O1)CC3CC(O2)CC=C(C(C(C=CC=C4COC5C4(C(C=C(C5O)C)C(=O)O3)O)C)OC6CC(C(C(O6)C)OC7CC(C(C(O7)C)O)OC)OC)C)C
|
|||||
| InChI |
InChI=1S/C48H74O14/c1-11-25(2)43-28(5)17-18-47(62-43)23-34-20-33(61-47)16-15-27(4)42(26(3)13-12-14-32-24-55-45-40(49)29(6)19-35(46(51)58-34)48(32,45)52)59-39-22-37(54-10)44(31(8)57-39)60-38-21-36(53-9)41(50)30(7)56-38/h12-15,19,25-26,28,30-31,33-45,49-50,52H,11,16-18,20-24H2,1-10H3/b13-12+,27-15+,32-14+/t25-,26-,28-,30-,31-,33+,34-,35-,36-,37-,38-,39-,40+,41-,42-,43+,44-,45+,47+,48+/m0/s1
|
|||||
| InChIKey |
AZSNMRSAGSSBNP-XPNPUAGNSA-N
|
|||||
| CAS Number |
CAS 71827-03-7
|
|||||
| Pharmaceutical Properties | Molecular Weight | 875.1 | Topological Polar Surface Area | 170 | ||
| Heavy Atom Count | 62 | Rotatable Bond Count | 8 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 14 | |||
| XLogP |
4.1
|
|||||
| PubChem CID | ||||||
| PubChem SID | ||||||
| ChEBI ID |
CHEBI:63941
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | MRP1 | Transporter Info | Multidrug resistance-associated protein 1 | Substrate | [2] | |
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
| References | ||||||
| 1 | Ivermectin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Interaction of ivermectin with multidrug resistance proteins (MRP1, 2 and 3). Chem Biol Interact. 2006 Feb 25;159(3):169-79. | |||||
| 3 | MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin. Eur J Pharmacol. 2003 Jan 24;460(2-3):85-91. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.